Literature DB >> 19772754

A simple and rapid method for the determination of pennogenin diglycoside in rat plasma by HPLC-MS: application to the pharmacokinetics of the extract in Gongxuening capsules.

Qingfei Liu1, Yun Shi, Yuzhen Zhang, Zhongmin Song, Qiang Su, Yu Zhang, Guoan Luo.   

Abstract

A sensitive, selective, and reproducible reversed-phase high-performance liquid chromatography method coupled with electrospray ionization-ion trap mass spectrometry (LC-ESI-ITMS) was developed for the simultaneous quantification of pennogenin diglycoside (PD) in a small volume (100 microL) of rat plasma. PD was extracted from rat plasma samples using liquid-liquid extraction with methanol, digoxin as internal standard. The chromatographic separation was performed on a reversed-phase Agilent C(18) (250 mm x 4.6 mm i.d., 5 mum particle size) analytical column using a mobile phase of 0.1% formic acid solution-acetonitrile (75:25, v/v) at a flow-rate of 1.0 mL/min. The mass spectrometer was operated in the negative ion mode at the deprotonated-molecular ions [M-H]- of parent drug. Calibration curve in spiked plasma was linear (correlation coefficient r = 0.999) from 0.5 to 50.0 mg/mL. For the different samples with concentration of 0.50, 5.00, and 50.0 microg/mL, recoveries of PD were (86.45 +/- 4.39)%, (91.40 +/- 4.40)%, and (93.79 +/- 3.29)%, respectively (n = 3). The intra-day assay relative standard deviation at 0.50, 5.00, and 50.0 mg/mL of PD were 4.29%, 5.66%, and 4.03% (n = 3), respectively. The inter-day assay %RSD at the previously mentioned concentrations were 5.53%, 4.99%, and 4.31% (n = 3), respectively. The method was successfully applied to the pharmacokinetic study of PD in rats following either intravenous administration of PD solution or oral administration of the extract in Gongxuening capsules, a famous patent Chinese botanic drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19772754     DOI: 10.1093/chromsci/47.8.728

Source DB:  PubMed          Journal:  J Chromatogr Sci        ISSN: 0021-9665            Impact factor:   1.618


  1 in total

1.  A Traditional Chinese Medicine for the Treatment of Endometrial Hyperplasia via Regulating the HPO Axis in Rats.

Authors:  Bo Lv; Yuan-de Peng; Wen-Hui Fu; Wen-Jing Li; Li-Jun Chen; Zhi Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-02-02       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.